BioNTech (BNTX) vs Incyte (INCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Incyte (INCY) has outperformed BioNTech (BNTX) over the past year, gaining 32.1% versus a loss of 13.4%. Over five years, INCY leads with a +72.0% price change compared with -62.8% for BNTX. BioNTech is the larger company by market cap ($24.12 billion vs $22.96 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BNTX | INCY |
|---|---|---|
| Share price | $96.03 | $113.27 |
| Market cap | $24.12B | $22.96B |
| 1-day change | +4.31% | +0.46% |
| YTD return | -3.30% | +14.15% |
| 1-year return | -13.38% | +32.06% |
| 5-year return | -62.83% | +71.98% |
| P/E ratio (TTM) | — | 14.43 |
| Forward P/E | — | 12.95 |
| EPS (TTM) | $-7.83 | $7.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $5.14B |
| Revenue growth (YoY) | — | +21.22% |
| Net income (latest FY) | — | $1.29B |
| Gross margin | — | 92.76% |
| Operating margin | — | 29.46% |
| Net margin | — | 25.03% |
| 52-week high | $124.00 | $132.60 |
| 52-week low | $79.52 | $82.82 |
| Distance from 52-week high | -22.56% | -14.58% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +20.58% | +14.00% |
| Average volume | 1.16M | 1.63M |
| Shares outstanding | 251.20M | 202.70M |
| Employees | 7,807 | 2,844 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INCY has outperformed BNTX by 45.4 percentage points over the past year.
About BioNTech
BNTX stock →BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,807 employees
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
BNTX vs INCY FAQ
Which is bigger, BioNTech or Incyte?
BioNTech (BNTX) is larger, with a market capitalization of $24.12B compared with $22.96B for Incyte (INCY).
Which stock has performed better over the past year, BNTX or INCY?
INCY returned +32.06% over the past 12 months, compared with -13.38% for BNTX (price return, excluding dividends). Past performance does not predict future results.
Are BioNTech and Incyte in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioNTech and Biotechnology: Commercial Physical & Biological Resarch for Incyte.